<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00696917</url>
  </required_header>
  <id_info>
    <org_study_id>208129/031</org_study_id>
    <nct_id>NCT00696917</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Volunteers ≥ 15y</brief_title>
  <official_title>Safety and Immunogenicity of 3 Lots of GSK Biologicals' Novel Adjuvanted Hepatitis B Vaccine, Administered According to a 2 Dose Schedule, and Engerix™-B Administered According to a 3 Dose Schedule to Healthy Volunteers ≥ 15 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study was conducted to evaluate the lot-to-lot consistency of three lots of HBV-MPL
      vaccine and to compare their safety and immunogenicity with that of Engerix™-B.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former
      name SmithKline Beecham
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1999</start_date>
  <primary_completion_date type="Actual">February 2000</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence, intensity and causal relationship of any (solicited/unsolicited adverse event) general symptoms</measure>
    <time_frame>Full course of vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse events</measure>
    <time_frame>Study period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-HBs antibody concentrations</measure>
    <time_frame>At Month 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence and intensity of solicited local signs and symptoms</measure>
    <time_frame>4-day after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence, intensity and relationship to vaccination of solicited general signs and symptoms</measure>
    <time_frame>4-day after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence, intensity and relationship to vaccination of unsolicited signs and symptoms</measure>
    <time_frame>30 days after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and relationship to vaccination of SAEs</measure>
    <time_frame>During the study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs antibody concentrations</measure>
    <time_frame>At Months 1, 2, 6 and 7</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1303</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three doses according to 0, 1, 6-month schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two doses according to 0, 6-month schedule, with a placebo injection at Month 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two doses according to 0, 6-month schedule, with a placebo injection at Month 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two doses according to 0, 6-month schedule, with a placebo injection at Month 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HBV-MPL vaccine 208129</intervention_name>
    <description>2-dose intramuscular injection 3 different vaccine lots</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engerix™-B</intervention_name>
    <description>3-dose intramuscular injection</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female aged ≥ 15 years at the time of the first vaccination. In Centre 103
             (Germany) and Centre 1 (Netherlands), only subjects ≥ 18 years will be enrolled.

          -  Free of obvious health problems as established by medical history and clinical
             examination before entering into the study.

          -  Written informed consent obtained from the subject and/or from the parent or guardian
             of the subject.

          -  If the subject was a female, she was of non-childbearing potential, if of childbearing
             potential, she was abstinent or used adequate contraceptive precautions for one month
             prior to enrollment and up to two months after the last vaccination

        Exclusion Criteria:

          -  Use of any investigational or non-registered drug or vaccine other than the study
             vaccine (s) during the study period or within 30 days preceding the first dose of
             study vaccine.

          -  Planned administration/ administration of a vaccine not foreseen by the study protocol
             during the period starting from 30 days before each dose of vaccine and ending 30 days
             after.

          -  Previous vaccination against hepatitis B.

          -  History of non-response to previous hepatitis B vaccination.

          -  Known exposure to hepatitis B within the past 6 weeks.

          -  History of hepatitis B infection.

          -  Confirmed human immunodeficiency virus (HIV) infection.

          -  A family history of congenital or hereditary immunodeficiency.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine.

          -  Acute disease at the time of enrollment.

          -  Hepatomegaly, right upper quadrant abdominal pain or tenderness.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the first dose of study vaccine or planned administration/ administration
             during the study period.

          -  Pregnant or lactating female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Hradec Kralové</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2008</study_first_submitted>
  <study_first_submitted_qc>June 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2008</study_first_posted>
  <last_update_submitted>June 11, 2008</last_update_submitted>
  <last_update_submitted_qc>June 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>Isabelle Harpigny</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>Adjuvanted Hepatitis B vaccine</keyword>
  <keyword>Recombinant Hepatitis B vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

